Diane Souza - Sanofi ADR Independent Director
| SNY Stock | USD 49.09 0.04 0.08% |
Director
Ms. Diane Souza has served as Independent Director of Sanofi S.A. since May 2016. She is Member of the Audit and Compensation Committees of the Company. She is the former CEO of United Healthcare Specialty Benefits. She is a member of the Board of Directors of Farm Credit East in the United States. She began her career with Price Waterhouse in 1979 as Audit Staff Accountant before assuming several senior positions at Deloitte Haskins Sells, from Audit Staff Accountant to Senior Tax ManagerinCharge, from 1980 to 1988. She returned to Price Waterhouse from 1988 to 1994, where she notably held the position of Head of the Northeast Insurance Tax Region. In 1994 Diane Souza joined Aetna and UnitedHealtcare in 2008. Former CEO of UnitedHealthcare Specialty Benefits, Diane Souza has over 25 years of managed care and health benefits experience, she led healthcare operations and business and largescale systems transformation at UnitedHealthcare and Aetna, as well as delivery of the integrated market strategy for the Affordable Care Act. She also served as CFO of Aetnas Guaranteed Products business, where she was regularly involved in complex financial transactions since 2016.
| Age | 65 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 46, avenue de la Grande Armée,, Paris, France, 75017 |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robson Walton | Walmart | 73 | |
| Robert Milton | Air Lease | 60 | |
| Thomas Horton | Walmart | 59 | |
| Debra ReedKlages | Chevron Corp | 63 | |
| Matthew Hart | Air Lease | 69 | |
| Ronald Sugar | Chevron Corp | 72 | |
| Shumeet Banerji | HP Inc | 61 | |
| Roger Corbett | Walmart | 71 | |
| Aida Alvarez | Walmart | 65 | |
| ron Sugar | Chevron Corp | 66 | |
| Inge Thulin | Chevron Corp | 64 | |
| Alice Gast | Chevron Corp | 61 | |
| Stacey Mobley | HP Inc | 73 | |
| Dambisa Moyo | Chevron Corp | 52 | |
| Jon Huntsman | Chevron Corp | 60 | |
| Kevin Systrom | Walmart | 32 | |
| Ronald Sugar | Air Lease | 70 | |
| Jim Walton | Walmart | 65 | |
| James Cash | Walmart | 68 | |
| Carl Bass | HP Inc | 58 | |
| Mary DePalma | Air Lease | N/A | |
Management Performance
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
| Emmanuel Babeau, Independent Director | ||
| Roy Papatheodorou, Executive Counsel | ||
| Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
| Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
| Dieter Weinand, Executive Vice President Member of the Executive Board | ||
| Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
| Eva SchaeferJansen, Head Relations | ||
| Fabienne Lecorvaisier, Director | ||
| George Grofik, Vice President of Investor Relations | ||
| Karen Linehan, Executive VP of Legal Affairs and General Counsel | ||
| Klaus Pohle, Independent Director | ||
| John Reed, President - Global Research & Development, Member of the Executive Committee | ||
| Bernard Charles, Independent Director | ||
| Natalie Bickford, Executive Officer | ||
| FranoisXavier Roger, Chief Officer | ||
| Melanie Lee, Independent Director | ||
| Madeleine Roach, Executive Operations | ||
| Pierre Chancel, Senior Marketing | ||
| Christophe Babule, Director | ||
| Bonnie Bassler, Director | ||
| Thomas Suedhof, Independent Director | ||
| Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
| Laurent Attal, Director | ||
| JeanRene Fourtou, Independent Director | ||
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Josephine Fubara, Chief Care | ||
| Christian Mulliez, Director | ||
| Robert Castaigne, Independent Director | ||
| Laurent Gilhodes, Principal Accounting | ||
| Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
| Uwe Bicker, Independent Director | ||
| Josep Catlla, Head Communications | ||
| Claudie Haignere, Independent Director | ||
| Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
| Paul Hudson, CEO Director | ||
| Bruno Mnard, Chief officer | ||
| Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
| Dante Beccaria, Global VP | ||
| Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
| William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
| Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
| David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
| Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
| Diane Souza, Independent Director | ||
| Carole Piwnica, Independent Director | ||
| Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
| Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
| Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
| Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
| DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
| Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
| Igor Landau, Director | ||
| Patrick Kron, Independent Director | ||
| Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
| Gerard Kemmel, Independent Director | ||
| SuetFern Lee, Independent Director | ||
| Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
| David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
| Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
| Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 71.37 B | ||||
| Shares Outstanding | 2.5 B | ||||
| Shares Owned By Institutions | 9.99 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.44 X |
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 2.3 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.